Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Patients With Malignant Mesothelioma
NCT02399371Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Mar 2015
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in malignant mesothelioma, sponsored by University of Chicago. Started Mar 2015; status: completed.
02
Drugs
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT02399371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399371.